ZYVOX Drug Patent Profile

When do Zyvox patents expire, and what generic alternatives are available?

Zyvox is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in ZYVOX is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyvox

A generic version of ZYVOX was approved as linezolid by HIKMA on June 3^rd, 2015.

Summary for ZYVOX

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	95
Patent Applications:	4,669
Drug Prices:	Drug price information for ZYVOX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYVOX
What excipients (inactive ingredients) are in ZYVOX?	ZYVOX excipients list
DailyMed Link:	ZYVOX at DailyMed

See drug prices for ZYVOX

Pharmacology for ZYVOX

Drug Class

Oxazolidinone Antibacterial

Paragraph IV (Patent) Challenges for ZYVOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYVOX	Injection	linezolid	2 mg/mL, 100 mL bag	021131	1	2009-12-29
ZYVOX	Injection	linezolid	2 mg/mL, 300 mL bag	021131	1	2009-09-01
ZYVOX	Oral Suspension	linezolid	100 mg/5 mL	021132	1	2009-08-03
ZYVOX	Tablets	linezolid	600 mg	021130	1	2005-12-21

US Patents and Regulatory Information for ZYVOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZYVOX	linezolid	FOR SUSPENSION;ORAL	021132-001	Apr 18, 2000	AB	RX	Yes	Yes
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-003	Apr 18, 2000	AP	RX	Yes	Yes
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-001	Apr 18, 2000	AP	RX	Yes	No
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-002	Apr 18, 2000		DISCN	Yes	No
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-002	Apr 18, 2000		DISCN	Yes	No

Expired US Patents for ZYVOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-002	Apr 18, 2000	6,559,305*PED
Pfizer	ZYVOX	linezolid	FOR SUSPENSION;ORAL	021132-001	Apr 18, 2000	5,688,792*PED
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-002	Apr 18, 2000	5,688,792*PED
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-003	Apr 18, 2000	6,559,305*PED
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-001	Apr 18, 2000	6,559,305*PED

International Patents for ZYVOX

See the table below for patents covering ZYVOX around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1054325	噁唑烷酮片劑的配方 (OXAZOLIDINONE TABLET FORMULATION)
China	1130379
Poland	356433
Eurasian Patent Organization	200200819
Czech Republic	20023133

Supplementary Protection Certificates for ZYVOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0717738	02C0005	France		PRODUCT NAME: LINEZOLIDE; NAT. REGISTRATION NO/DATE: NL 26 660 20010831; FIRST REGISTRATION: GB - PL 00 32/0261 20010105
0717738	PA2004004	Lithuania		PRODUCTNAME: LINEZOLIDUM - (S)-N-[[3-FLUOR-4-(4-MORFOLINIL)FENIL]-2-OKSO-5-OKSAZOLIDINIL]METIL]-ACETAMIDAS
0717738	SPC001/2002	Ireland		SPC001/2002: 20031204, EXPIRES: 20160104
0717738	CA 2002 00004	Denmark
0717738	PA2004004,C0717738	Lithuania		PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313

Market Dynamics and Financial Trajectory for ZYVOX

Last updated: February 19, 2026

What is the current market position of ZYVOX?

ZYVOX (linezolid) is an oxazolidinone antibiotic developed by Pfizer. Approved by FDA in 2000 for complicated skin and soft tissue infections and nosocomial pneumonia, ZYVOX maintains a niche in resistant Gram-positive infections. As of 2023, Pfizer holds the exclusive patent rights, with no significant generic competition.

Key Market Data

• Global sales in 2022: approximately $370 million.
• Revenue decline: 10% compared to 2021 due to generic erosion in some markets.
• Major markets: United States (70%), Europe (20%), rest of the world (10%).

Market Share in Antibiotics

• Estimated 15% share among hospital-administered therapies for resistant Gram-positive infections.
• Competing drugs: vancomycin, daptomycin, ceftaroline.
• ZYVOX's unique feature: oral and IV formulations, simplifying outpatient treatment.

How do patent and exclusivity statuses impact the financial outlook?

The initial patent expired in 2015 in many jurisdictions, but Pfizer secured a 7-year pediatric exclusivity extension, valid until 2022, delaying generic entry.

Patent Status

Region	Patent expiry	Exclusivity extension	Implication
US	2015	Yes (until 2022)	Limited generic competition
Europe	2015	No	Generic versions available in 2016
Australia	2018	No	Generics entered earlier

Generic Competition

• Generics launched in Europe and Australia in 2016–2018.
• In the US, ZYVOX remains under patent protection until 2022 (extended to 2022 due to pediatric exclusivity).
• Post-2022, revenue decline projected due to increased generic uptake.

What are the current and projected sales trends?

Short-term Trends (Next 2 Years)

• Slight revenue decline anticipated year-over-year (YoY) due to generic competition.
• Sales expected to decrease by 15-20%, reaching around $300 million in 2024.

Long-term Outlook (Beyond 2024)

• Revenue erosion continues as generic versions gain market share.
• Estimated 40–50% decline over the next 5 years if no new formulations or indications develop.
• Potential stabilization if new indications or combination therapies gain approval.

What factors influence future growth prospects?

Off-Label and New Indications

• No recent approvals for new indications.
• Some exploratory studies target resistant bacterial strains, but no significant pipeline developments.

Patent Litigation and Market Entry

• Pfizer defends patent rights aggressively, especially in the US.
• Risk exists of patent litigation delaying generic entry or keeping formulations exclusive longer.

Pricing Strategies

• Pfizer maintains premium pricing for branded ZYVOX.
• Post-patent expiration, price reductions expected (~30–50%), per industry standards.

Competitive Landscape

• Alternatives like daptomycin and linezolid (Xenleta) affect market share.
• Shift toward oral antibiotics reduces hospital stay costs, favoring oral formulations like ZYVOX.

How do external factors impact revenue?

Healthcare Policy and Reimbursement

• US Medicare and Medicaid policies favor cost-effective antibiotics, pressuring prices.
• Value-based pricing models may limit revenue potential.

Global Market Variability

• Emerging markets exhibit slower adoption of generic versions.
• Better growth potential in countries with delayed patent enforcement and less generic competition.

Impact of COVID-19

• Hospital resource reallocation affected antibiotic prescribing patterns.
• Shift toward outpatient treatments favors orally administered drugs like ZYVOX.

Summary of Investment and R&D Outlook

• Pfizer’s focus remains on maintaining ZYVOX’s market share via patent protection and expansion into new territories.
• R&D efforts for novel formulations or indications have been limited; strategic focus on combating resistance may influence future pipeline decisions.
• Long-term revenues will depend heavily on patent litigation outcomes, regulatory approvals for new uses, and market acceptance of generics.

Key Takeaways

• ZYVOX’s revenue peaked pre-2015; post-patent expiration, sales decline sharply.
• Patent protections and exclusivity extensions currently delay generics, sustaining revenue.
• Market competition from generics and alternative antibiotics reduces future earnings potential.
• External factors like healthcare policies and global market dynamics influence sales trajectories.
• Long-term growth relies on pipeline innovation, new indications, and market position defense strategies.

FAQs

1. When will ZYVOX face significant generic competition in the US?
Patent rights were extended until 2022 due to pediatric exclusivity. Generics are expected to enter the US market afterward, likely leading to revenue declines.

2. Are there efforts to introduce new formulations or indications for ZYVOX?
No recent approvals for new indications or formulations have been announced; existing research is limited.

3. How does the competition compare in efficacy and cost?
Daptomycin and linezolid offer similar efficacy with comparable cost structures. Generic versions of linezolid are also available, impacting ZYVOX’s market share.

4. What is the potential impact of legal disputes on ZYVOX’s revenue?
Patent litigation could delay generic entry or extend exclusivity protections, preserving revenue temporarily but unlikely to prevent eventual generic competition.

5. How can Pfizer mitigate revenue decline for ZYVOX?
Strategies include expanding indications, reducing prices strategically, and leveraging oral formulations for outpatient care.

---

References

[1] Pfizer Inc. (2023). ZYVOX (linezolid) prescribing information. Pfizer.
[2] MarketWatch. (2023). ZYVOX sales data and competitive analysis.
[3] FDA. (2022). Drug patent and exclusivity information.
[4] IQVIA. (2023). Global Antibiotics Market Report.
[5] European Medicines Agency. (2016). Linezolid Market Entry Review.